
Ruben J Colman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2342726/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibodiesâ€toâ€infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 593-603.	3.7	22
2	Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, 1045-1051.	1.9	14
3	Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory Bowel Diseases, 2021, 27, 507-515.	1.9	21
4	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. Frontiers in Pediatrics, 2021, 9, 634739.	1.9	7
5	Realâ€World Infliximab Pharmacokinetic Study Informs an Electronic Health Recordâ€Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1639-1647.	4.7	38
6	1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE. Gastroenterology, 2020, 158, S-233-S-234.	1.3	0
7	Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. Gastroenterology, 2020, 158, S-967-S-968.	1.3	0
8	613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. Gastroenterology, 2020, 158, S-130-S-131.	1.3	0
9	An 11-Month-Old With Vomiting, Altered Mental Status, and Hypoventilation. Clinical Pediatric Emergency Medicine, 2020, 21, 100764.	0.4	0
10	22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN'S DISEASE (CD). Gastroenterology, 2020, 158, S112.	1.3	0
11	Efficacy and Follow-up of Segmental or Subtotal Colectomy inÂPatients With Colitis-Associated Neoplasia. Clinical Gastroenterology and Hepatology, 2019, 17, 205-206.	4.4	21
12	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 486-493.	4.4	76
13	Upper Gastrointestinal Endoscopy in Adolescents With Severe Obesity Before Vertical Sleeve Gastrectomy. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 287-291.	1.8	5
14	Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases, 2018, 24, 2135-2141.	1.9	30
15	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases, 2018, 24, 849-860.	1.9	34
16	Prevalence of functional GI disorders among pediatric patients with persistent asthma. Journal of Digestive Diseases, 2018, 19, 522-528.	1.5	7
17	P-031â€fYlâ€fSegmental and Total Abdominal Colectomies are Safe Management Strategies for Colitis-Associated Neoplasia. Inflammatory Bowel Diseases, 2016, 22, S19.	1.9	0
18	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflammatory Bowel Diseases, 2016, 22, 631-637.	1.9	27

Ruben J Colman

#	Article	IF	CITATIONS
19	Sa1970 Antibodies to Infliximab are Frequently Present when Infliximab Levels are Detectable in an ECLIA-based Assay. Gastroenterology, 2016, 150, S420.	1.3	0
20	Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intestinal Research, 2016, 14, 202.	2.6	48
21	Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash. ACG Case Reports Journal, 2015, 2, 236-238.	0.4	8
22	Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 312-317.	1.3	35
23	Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience. Gastroenterology, 2015, 148, S-866.	1.3	5
24	Sa1998 "But I'm Feeling Fine!―A Comparison of Parent and Child Symptom-Report Among Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology, 2015, 148, S-379-S-380.	1.3	1
25	Sa1141 Assessment of Injection Site Reactions Related to Anti-TNF Therapies in Inflammatory Bowel Disease. Gastroenterology, 2015, 148, S-238.	1.3	Ο
26	Tu1351 Crohn's Disease Patients Currently or Previously on Natalizumab Can Be Safely and Effectively Switched to Vedolizumab. Gastroenterology, 2015, 148, S-866-S-867.	1.3	0
27	Tu1349 The Efficacy and Safety of Calcineurin Inhibitors in Inducing and Maintaining Clinical Remission in IBD Patients Commencing Vedolizumab. Gastroenterology, 2015, 148, S-866.	1.3	Ο
28	Su2014 Revised Predictive Values for IBD Colitis-Associated Neoplasia in the Modern Era. Gastroenterology, 2015, 148, S-575.	1.3	0
29	Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab. American Journal of Gastroenterology, 2015, 110, S783-S784.	0.4	4
30	Can Baseline Histological Score Predict Subsequent Clinical Outcomes in Patients With Ulcerative Colitis?. American Journal of Gastroenterology, 2015, 110, S799.	0.4	0
31	Efficacy of High-Dose Versus Low-Dose Methotrexate in Combination Therapy for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, S489-S490.	0.4	Ο
32	Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 1569-1581.	1.3	388
33	Fecal Alpha 1-Antitrypsin as a Biomarker for Disease Activity in Ulcerative Colitis. American Journal of Gastroenterology, 2014, 109, S434.	0.4	1
34	Agreement Between Patient―and Physicianâ€completed Pediatric Ulcerative Colitis Activity Index Scores. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 708-713.	1.8	20